Veracyte (VCYT) Accumulated Expenses (2012 - 2026)

Veracyte (VCYT) has 15 years of Accumulated Expenses data on file, last reported at $43.1 million in Q1 2026.

• Quarterly Accumulated Expenses rose 20.04% year-over-year to $43.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $43.1 million (up 20.04% YoY) and the FY2025 annual result came in at $48.8 million, up 11.35% from the prior year.
• Accumulated Expenses retreated to $43.1 million in Q1 2026 per VCYT's latest filing, from $48.8 million in the prior quarter.
• The five-year high for Accumulated Expenses was $48.8 million in Q4 2025, with the low at $30.3 million in Q1 2024.
• Average Accumulated Expenses over 5 years is $38.9 million, with a median of $38.4 million recorded in 2023.
• Year-over-year, Accumulated Expenses surged 137.13% in 2022 and decreased 20.5% in 2023.
• Veracyte's Accumulated Expenses stood at $37.8 million in 2022, then climbed by 1.73% to $38.4 million in 2023, then gained by 14.05% to $43.8 million in 2024, then gained by 11.35% to $48.8 million in 2025, then dropped by 11.62% to $43.1 million in 2026.
• Business Quant data shows VCYT's Accumulated Expenses at $43.1 million in Q1 2026, $48.8 million in Q4 2025, and $48.4 million in Q3 2025.